Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia
Key facts
- Who runs it
- Bing Han
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 58 people enrolled
- Started
- 19 Dec 2022
- Ended
- 15 Apr 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Luspatercept
- Cyclosporine
- Record updated
- 16 September 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- age≥18 year-old
- hemoglobin level between 60g/L~10 g/dL
- newly diagnosed patients have at least one of the followings: #absolute neutrophil count <1.5×109/L, #platelet count < 30×109/L, # hemoglobin level < 100g/L
- with normal baseline liver and kidney function
- with no active infection; are not pregnant or nursing
- agree to sign consent forms
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Who cannot take part
- Patients received HSCT before
- Have any concomitant malignancies within 5 years expect for local basal cell carcinoma of the skin
- Evidence of a clonal hematologic bone marrow disorder (MDS, AML) on cytogenetics
- Uncontrolled infection or bleeding with standard treatment
- Allergic to luspatercept CsA or accessories
- HIV, HCV or HBV active infection or liver cirrhosis or portal hypertension
- Past history of thromboembolic event, heart attack or stroke (including anti-phospholipid antibody syndrome) and current use of anticoagulants
- Patient with QTcF (Fridericia's QT correction formula) at screening <450 msec, or<480 msec with bundle branch block, as determined via the mean of a triplicate ECG and assessed at site, unstable angina pectoris, uncontrolled hypertension(>180/100mmHg)#pulmonary artery hypertension
- Congenital aplastic anemia
- Presence of chromosomal aberration
- Presence with PNH clone ≥50%
- Pregnant or nursing (lactating) woman
- Have attended other clinical trials within 3 months
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Aplastic anemia (AA) is a rare bone marrow failure disease characterized by bone marrow hypocellularity and peripheral blood pancytopenia. AA is divided into severe AA (SAA) and non-severe AA (NSAA) based on the degree of cytopenia. The first line therapy for SAA or transfusion dependent NSAA is either immunosuppression therapy (IST) or hematopoietic stem cell transplantation (HSCT). Little attention has been paid to patients with anemia but not transfusion dependent, whose quality of life is significantly impaired due to the anemia and other complications.
The 2 groups in the trial
- efficiency and safety in luspatercept plus cyclosporineTreatment being tested
luspatercept is at a dose of 1.0 mg per kilogram of body weight, administered subcutaneously every 3 weeks,and cyclosporine is at a dose of 3\~5mg/kg /day for at least 6 months.
Treatment: Luspatercept and Cyclosporine
- controll group in cyclosporine aloneExisting treatment, for comparison
cyclosporine is at a dose of 3\~5mg/kg /day for at least 6 months.
Treatment: Cyclosporine
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Case Controlled Clinical Trial Evaluating the Efficiency and Safety of Luspatercept Plus Cyclosporine Versus Cyclosporine in Newly Diagnosed Transfusion Independent Non-severe Aplastic Anemia (NSAA).
- Publications
- Record updated
- 16 September 2025